COMMUNIQUÉS West-GlobeNewswire

ORYZON to Participate in Upcoming Events in November
30/10/2025
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today [...]
Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025
30/10/2025
BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, [...]
UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
30/10/2025
Conference Call and Webcast Scheduled for Thursday, November 6th, 2025, at 10:00 AM ET PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and [...]
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
30/10/2025
Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2 ZORYVE cream 0.05% provides rapid clearance of atopic dermatitis ZORYVE can be used anywhere [...]
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
30/10/2025
SUNNYVALE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
Veru Announces Pricing of $25 Million Public Offering
30/10/2025
MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
30/10/2025
Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology’s immunotherapy platforms PRINCETON, N [...]
MediBeacon to Present at the Upcoming American Society of Nephrology (ASN) Kidney Week 2025
30/10/2025
ST. LOUIS, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MediBeacon Inc. , a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, today announced that data from [...]
Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025
30/10/2025
BASKING RIDGE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]
23andMe Research Institute Appoints Privacy Advisory Board
30/10/2025
PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, today announced the formation of its Privacy Advisory Board. Composed of leading experts in [...]
Glass House Brands to Host Third Quarter 2025 Earnings Call on November 12, 2025
30/10/2025
LONG BEACH, Calif. and TORONTO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. (“Glass House” or the “Company”) (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor
30/10/2025
PALM BEACH GARDENS, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc (“Forward”), a biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced that [...]
Tilray Brands Sets Sights on Asia: Bringing Award-Winning Craft Beers to Japan’s Premier American Craft Beer Experience Festival
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is [...]
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
30/10/2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on [...]
Cambridge Atomworks is delighted to announce the appointment of Mr Alistair Pettey as a non-executive director
30/10/2025
CAMBRIDGE, United Kingdom, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Alistair will lead on the growth and capital strategy for Cambridge Atomworks. Alistair has a passion for investing in companies that have a strong focus in [...]
Eagle Pharmaceuticals Board Extends Limited Duration Stockholder Rights Plan
30/10/2025
WOODCLIFF LAKE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has adopted an amendment (the “ [...]
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
30/10/2025
$12.9 million in third quarter PYRUKYND ® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision [...]
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
30/10/2025
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific LOUISVILLE, Colo., Oct. 30, 2025 ( [...]
TOLREMO therapeutics Welcomes Multiple Myeloma Leader Kenneth C. Anderson to its Scientific Advisory Board
30/10/2025
Basel, October 30, 2025 – TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Kenneth C. Anderson, MD, a globally recognized leader in multiple myeloma research, to the company’s Scientific Advisory [...]

Pages